Fish oil in the treatment of dyslipidemia

Ronald B. Goldberg, Anup K. Sabharwal

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


PURPOSE OF REVIEW: The recent availability of a concentrated prescription ω-3 fatty acid preparation provides physicians with an additional antidyslipidemic agent at a time when limitations of statin therapy in dyslipidemic high-risk patients are recognized. This review examines the evidence supporting the use of ω-3 fatty acid treatment in dyslipidemic states. RECENT FINDINGS: There is now considerable evidence that ω-3 fatty acid treatment at the prescription strength of 4 g/day effectively and safely lowers triglyceride levels and increases low-density lipoprotein size, as well as affecting high-density lipoprotein metabolism. Similar effects have been noted in patients treated with statins, and add-on prescription ω-3 fatty acid therapy significantly increases the proportion of statin-treated dyslipidemic patients reaching their non-high-density lipoprotein cholesterol goals. In addition to past studies showing a cardioprotective effect of low-dose ω-3 fatty acid treatment against sudden death, a recent controlled clinical trial showed that 1.8 g of ω-3 fatty acid in statin-treated patients reduced major coronary events by 19% compared with statin plus placebo treatment. SUMMARY: Omega-3 fatty acid treatment should be considered in patients with severe hypertriglyceridemia as well as in high-risk patients with an atherogenic lipoprotein phenotype.

Original languageEnglish (US)
Pages (from-to)167-174
Number of pages8
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number2
StatePublished - Apr 2008


  • ω-3 fatty acid
  • Dyslipidemia

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics
  • Medicine(all)


Dive into the research topics of 'Fish oil in the treatment of dyslipidemia'. Together they form a unique fingerprint.

Cite this